Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

Today, the FDA issued draft guidance outlining a new regulatory pathway intended to help sponsors gain approval for highly ...

Over the long term, Levin expects oral GLP-1s to gain favor over injectables. Most patients prefer pills to injections, and ...

Development assistance for health has fallen back toward 2010 levels, disproportionately disrupting community-based HIV services and projecting increased infections and AIDS-related deaths.

Digital health record integration boosts medication safety, as OTC use rivals prescription use in chronic care management, found a new study led by Jody L. Green, PhD, Uprise Health.

This poster reaffirms tirzepatide’s use in patients with HIV. As patients with HIV are diagnosed with diabetes at a higher rate, it is important that GLP-1 RAs are known to be safe and effective for ...

The FDA has approved a label expansion for tirzepatide (Zepbound; Eli Lilly), allowing use of a 4-dose, single-patient-use KwikPen that delivers a full month of treatment in 1 device for chronic ...

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

Ultimately, effective treatment selection integrates rigorous evaluation of evidence with individualized discussions of safety, efficacy, convenience, and patient values. By tailoring therapy to ...

Incremental dose to neurogenic niches correlated with reduced overall survival: SVZ HR 1.306/Gy and hippocampus HR 1.222/Gy, indicating independent adverse prognostic impact.

Two large real-world analyses presented at ACTRIMS Forum 2026 shed new light on the multiple sclerosis (MS) care continuum, ...